A detailed history of Royal Bank Of Canada transactions in Chroma Dex Corp. stock. As of the latest transaction made, Royal Bank Of Canada holds 200,760 shares of CDXC stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200,760
Previous 199,605 0.58%
Holding current value
$1.06 Million
Previous $544,000 34.56%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.51 - $3.8 $2,899 - $4,389
1,155 Added 0.58%
200,760 $732,000
Q2 2024

Aug 14, 2024

BUY
$2.44 - $4.32 $35,572 - $62,981
14,579 Added 7.88%
199,605 $544,000
Q1 2024

Nov 05, 2024

SELL
$1.36 - $3.84 $19,827 - $55,983
-14,579 Reduced 7.3%
185,026 $643,000
Q1 2024

May 15, 2024

BUY
$1.36 - $3.84 $89,738 - $253,378
65,984 Added 55.43%
185,026 $643,000
Q4 2023

Feb 14, 2024

BUY
$1.28 - $1.6 $44,093 - $55,116
34,448 Added 40.72%
119,042 $170,000
Q3 2023

Nov 14, 2023

SELL
$1.36 - $1.77 $478 - $623
-352 Reduced 0.41%
84,594 $123,000
Q2 2023

Aug 14, 2023

BUY
$1.31 - $1.79 $1,121 - $1,532
856 Added 1.02%
84,946 $133,000
Q1 2023

May 15, 2023

SELL
$1.48 - $2.19 $235 - $348
-159 Reduced 0.19%
84,090 $128,000
Q4 2022

Feb 14, 2023

BUY
$1.25 - $1.94 $10,755 - $16,691
8,604 Added 11.37%
84,249 $141,000
Q3 2022

Nov 14, 2022

BUY
$1.19 - $2.06 $90,017 - $155,828
75,645 New
75,645 $93,000
Q2 2022

Aug 15, 2022

SELL
$1.59 - $2.7 $4,579 - $7,776
-2,880 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.02 - $3.92 $14,618 - $28,369
-7,237 Reduced 71.53%
2,880 $7,000
Q4 2021

Feb 14, 2022

BUY
$3.74 - $6.7 $17,334 - $31,054
4,635 Added 84.55%
10,117 $38,000
Q3 2021

Nov 15, 2021

BUY
$6.05 - $10.41 $13,751 - $23,661
2,273 Added 70.83%
5,482 $35,000
Q2 2021

Aug 16, 2021

BUY
$6.66 - $10.92 $21,371 - $35,042
3,209 New
3,209 $32,000

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $362M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.